Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Equity Average (2020 - 2025)

Ovid Therapeutics' Equity Average history spans 6 years, with the latest figure at $87.7 million for Q4 2025.

  • For Q4 2025, Equity Average rose 21.34% year-over-year to $87.7 million; the TTM value through Dec 2025 reached $87.7 million, up 21.34%, while the annual FY2025 figure was $99.4 million, 27.47% up from the prior year.
  • Equity Average reached $87.7 million in Q4 2025 per OVID's latest filing, up from $50.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $213.9 million in Q2 2021 to a low of $50.2 million in Q3 2025.
  • Average Equity Average over 5 years is $118.8 million, with a median of $110.9 million recorded in 2023.
  • Peak YoY movement for Equity Average: surged 422.19% in 2021, then crashed 39.17% in 2025.
  • A 5-year view of Equity Average shows it stood at $188.4 million in 2021, then fell by 27.19% to $137.2 million in 2022, then plummeted by 31.07% to $94.5 million in 2023, then fell by 23.57% to $72.3 million in 2024, then grew by 21.34% to $87.7 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Equity Average are $87.7 million (Q4 2025), $50.2 million (Q3 2025), and $57.5 million (Q2 2025).